Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 33-42

  Fuhrman, Barbara J ^a   Teter, Barbara E ^b   Barba, Maddalena ^a   Byrne, Celia ^e   Cavalleri, Adalberto ^f   Grant, Brydon J ^c,d   Horvath, Peter J ^d   Morelli, Daniele ^f   Venturelli, Elisabetta ^f   Muti, Paola C ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EQUOL;

ADULT; AGED; ARTICLE; BODY MASS; BREAST; COMPUTER ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOLOGY; SOYBEAN; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BREAST; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DIET; FEMALE; HUMANS; ISOFLAVONES; MAMMOGRAPHY; MIDDLE AGED; PHYTOESTROGENS; POSTMENOPAUSE; QUESTIONNAIRES; SOY FOODS; SOYBEAN PROTEINS;

EID: 38849100876     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0193     Document Type: Article

References (57)

1. Cancer incidence in five continents. Parkin D, Whelan S, Ferlay J, Raymond L, Young J, editors. Vol. VII. Lyon, France: IARC Sci Publ; 1997.
2. Buell P. Changing incidence of breast cancer in Japanese American Women. J Natl Cancer Inst 1973;51:1479-83.
3. Schimizu H, Ross RK, Bernstein L. Cancers of the prostate and breast among Japanese and White immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
4. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85:1819-27.
5. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991;83:541-6.
6. Adlercreutz H, Mousavi Y, Clark J, et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol 1992;41:331-7.
7. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17:353-81.
8. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483-8.
9. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-6.
10. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98:1275-84.
11. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006;98:459-71.
12. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol - a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-84.
13. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005;230:155-70.
14. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-9.
15. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
16. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects withtime, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
17. Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486-92.
18. Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998;18:1587-98.
19. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
20. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated within itiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
21. Boyd N, Rommens JH, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808.
22. Maskarinec G, Meng L. An investigation of soy intake and mammographic characteristics in Hawaii. Breast Cancer Res 2001;3:134-41.
23. Jakes RW, Duffy SW, Ng FC, et al. Mammographic parenchymal patterns and self-reported soy intake in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:608-13.
24. Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev 2003;12:165-9.
25. Atkinson C, Warren RM, Sala E, et al. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Res 2004;6:R170-9.
26. Maskarinec G, Takata Y, Franke AA, Williams AE, Murphy SP. A 2-year soy intervention in premenopausal women does not change mammographic densities. J Nutr 2004;134:3089-94.
27. Kirk P, Patterson RE, Lampe J. Development of a soy food frequency questionnaire to estimate isoflavone consumption in US adults. J Am Diet Assoc 1999;99:558-63.
28. Williams AE, Maskarinec G, Hebshi S, Oshiro C, Murphy S, Franke AA. Validation of a soy questionnaire withrepeated dietary recalls and urinary isoflavone assessments over one year. Nutr Cancer 2003;47:118-25.
29. Umphress ST, Murphy SP, Franke AA, Custer LJ, Blitz CL. Isoflavone content of foods withsoy additives. J Food Comp Anal 2005;18:533-50.
30. Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 2006;54:184-201.
31. Horn-Ross PL, Barnes S, Lee M, et al. Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer Causes Control 2000;11:289-98.
32. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998;217:335-9.
33. Frankenfeld CL, Atkinson C, Thomas WK, et al. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 2005;94:873-6.
34. Venturelli E, Rinaldi S, Cambie M, Cavalleri A, Secreto G. Quantitative analysis of urinary daidzein and equol by gas chromatography after solid-phase extraction and high-performance liquid chromatography. Int J Biol Markers 2002;17:182-8.
35. Cumulus3 program. Sunnybrook and Women's College Health Sciences Centre; 2006.
36. Stuedal A, Gram IT, Bremnes Y, Adlercreutz H, Veierod MB, Ursin G. Plasma levels of enterolactone and percentage mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:2154-9.
37. Haars G, van Noord PA, van Gils CH, Grobbee DE, Peeters PH. Measurements of breast density: no ratio for a ratio. Cancer Epidemiol Biomarkers Prev 2005;14:2634-40.
38. Martinez ME. Soy and breast cancer: the controversy continues. J Natl Cancer Inst 2006;98:430-1.
39. Messina M. Western soy intake is too low to produce health effects. Am J Clin Nutr 2004;80:528-9; author reply 529-30.
40. Frankenfeld CL, McTiernan A, Aiello EJ, et al. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:1156-62.
41. Nettleton JA, Greany KA, Thomas W, Wangen KE, Adlercreutz H, Kurzer MS. The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. J Nutr 2005;135:603-8.
42. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
43. Cauley JA, Zmuda JM, Danielson ME, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003;14:740-4.
44. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005;14:2137-42.
45. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;(27):75-93.
46. Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF. Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol Biomarkers Prev 2006;15:1620-9.
47. Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702.
48. Vrieling A, Rookus MA, Kampman E, et al. Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk. J Nutr 2007;137:379-83.
49. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens withmammo graphic densities. Br J Cancer 2002;87:876-82.
50. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growthfacto r (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
51. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growthfa ctor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006;13:583-92.
52. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growthfactors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704.
53. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006;13:273-8.
54. Gold EB, Bair Y, Zhang G, et al. Cross-sectional analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic group and menopausal status: the Study of Women's Health Across the Nation (SWAN). Menopause 2007;14:612-23.
55. Setchell KD, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr 2006;136:2188-93.
56. Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991;54:1093-100.
57. Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 2000;36:27-32.